玻璃体切除术联合巩膜外环扎治疗脉络膜脱离型视网膜脱离

目的：探讨玻璃体切除联术合巩膜外环扎治疗脉络膜脱离型视网膜脱离的临床疗效。

方法：回顾性分析2014-01/2018-02在我院行玻璃体切除术联合巩膜外环扎治疗的脉络膜脱离型视网膜脱离患者19例19眼,术后3～12mo行玻璃体腔硅油取出术。观察患者术后视网膜复位率、眼压、视力恢复及并发症情况。

结果：本组患者术后视网膜均复位,术后3mo患眼玻璃体腔硅油填充状态下眼压(16.09±3.58mmHg)、硅油取出术后6mo眼压(14.69±3.10mmHg)均高于术前(6.78±1.90mmHg)(均P<0.05)。硅油取出术后6mo,15眼患者视力较术前提高。术后无低眼压及眼球萎缩等并发症发生。

结论：玻璃体切除术联合巩膜外环扎治疗脉络膜脱离型视网膜脱离是相对安全有效的,视网膜复位率高,术后并发症少,再次手术率低。     

27G玻璃体切除原位切膜法治疗晚期增殖性糖尿病视网膜病变

目的：探讨27G玻璃体切除原位切膜法治疗晚期增殖性糖尿病视网膜病变(PDR)的临床疗效。

方法：收集2017-01/08晚期PDR 10例15眼临床病例,行27G微创玻璃体切除术,采用切割头原位切膜法切除增殖膜,观察术中医源性视网膜裂孔发生率、硅油填充率、术前术后最佳矫正视力、眼压等指标。

结果：患者4眼(27%,4/15)术中发生医源性视网膜裂孔; 6眼(40%,6/15)硅油填充; 术后3mo时仅2眼视力不提高,13眼术后视力提高,最好视力0.6,术前最佳矫正视力分别与术后7d,1、3mo最佳矫正视力比较,差异均有统计学意义(P<0.05); 术前平均眼压16.95±6.87mmHg,术后3mo平均眼压15.27±4.57mmHg,两者比较差异无统计学意义(P>0.05)。

结论：27G玻璃体切除原位切膜法在晚期PDR术中处理视网膜前增殖膜时优势明显,疗效确切,可为晚期复杂PDR的优选术式。     

玻璃体切除术后视网膜脱离的临床观察

目的：探讨玻璃体切除术后视网膜脱离的原因、特点。方法：回顾性分析在我院近4 a行20 G标准三通道玻璃体切除手术的患者病例资料,术后发生视网膜脱离的病例纳入研究对象,分析视网膜脱离的特点及处理。术后发生视网膜脱离共23例24眼。年龄24～67（平均49．0±12．0）岁。男17例18眼,女6例6眼。右眼6眼,左眼18眼。结果：视网膜脱离的24眼中,18眼（75％）无任何症状,为常规检查时所发现;6眼（25％）为视力下降或眼前黑影遮挡就诊时发现。视网膜脱离距离玻璃体切除术后的时间1～223（平均40．7±54．2）d,其中10眼（42％）发生于1wk内,14眼（58％）发生于1 mo内。视网膜脱离的直接原因中：新发视网膜裂孔19眼,共27个裂孔;增殖性玻璃体视网膜病变（ PVR）4眼;原裂孔未封闭1眼。所有视网膜脱离最终均完全复位。结论：视网膜新裂孔的发生是导致玻璃体切除术后视网膜脱离的最主要原因,应重视术后早期周边视网膜的检查;经过及时的再次手术,视网膜均可得以复位。     

微创折叠球囊巩膜外加压治疗孔源性视网膜脱离的临床研究

目的:探讨微创折叠球囊巩膜外加压治疗孔源性视网膜脱离(RRD)的临床效果。方法:回顾性研究。收集2023-05/07于我院采用折叠球囊行微创巩膜外加压术连续治疗的RRD患者11例11眼,术中均采用结膜下麻醉、不做肌肉牵拉线、不做术中视网膜裂孔定位,不做视网膜冷冻和视网膜下放液、不做球囊巩膜固定缝线,观察手术最佳矫正视力(BCVA)、眼压和术后并发症。结果:纳入11眼中视网膜成功复位10眼(91%),1眼(9%)术后视网膜再脱离,因多发视网膜裂孔行玻璃体切除联合硅油填充术。成功行球囊顶压手术的10眼中球囊顶压一次成功4眼(40%),球囊顶压后行玻璃体注气1眼(10%),球囊顶压后再次调位3眼(30%),球囊顶压后再次调位及玻璃体腔注气2眼(20%);5眼(50%)术后4-12 wk行球囊取出,视网膜脱离无复发;术前平均最佳矫正视力(LogMAR)为1.30±1.10,术后4 wk为0.37±0.39(P<0.01);术前平均眼压11.51±3.37 mmHg,术后4 wk为13.72±2.57 mmHg(P>0.05)。所有患者术后均未发生严重并发症。结论:微创折叠球囊巩膜外...     

23G与25G+玻璃体切割手术治疗视网膜脱离的对比分析

目的：：比较23 G与25 G+玻璃体切割手术治疗孔源性视网膜脱离的临床疗效。方法：回顾性病例研究。回顾47例47眼单纯孔源性视网膜脱离患者分别接受23 G玻璃体切割手术( A组27例27眼)和25 G+玻璃体切割手术( B组20例20眼)。记录手术时间和术中并发症的发生情况。观察术后视力、眼压及视网膜复位情况,两组术后随访时间分别为3d,1wk,3mo,对相关记录进行统计学分析比较。结果：23 G组和25 G+组的手术时间分别为50.21±4.52、49.15±5.14min,两组平均手术时间比较,差异无统计学意义(P>0.05)。术中主要并发症为视网膜出血、医源性裂孔,23 G组为5眼(其中视网膜出血3眼、医源性裂孔2眼),25 G+组为2眼(其中视网膜出血1眼、医源性裂孔1眼),差异有统计学意义(P<0.05)。23G组和25G+组术后视力均较术前提高,两组间术后视力各时间点比较差异均无统计学意义(P>0.05)。23G、25G+两组术后3d低眼压分别为3眼和1眼,差异有统计学意义(P<0.05),但术后1wk和3mo,两组间眼压差异无统计学意义(P>0.05)。术后3 mo 结果显示23 G 组视网膜复位26眼(复位率96%),25 G+组视网膜复位19眼(复位率95%),差异无统计学意义(P>0.05)。结论：23 G与25 G+玻璃体切割手术治疗孔源性视网膜脱离的临床疗效相近,但25 G+玻璃体切割术可减少术中并发症及降低手术后早期低眼压的发生。     

改良穿刺放液在23G玻璃体切除治疗脉络膜脱离型视网膜脱离中的疗效

目的：观察巩膜全层切开、原位穿刺放液术在微创玻璃体切除术治疗脉络膜脱离型视网膜脱离中的安全性和临床疗效。

方法：临床病例回顾性分析。纳入2015-04/2017-04江苏省人民医院眼科住院治疗的脉络膜脱离型视网膜脱离患者20例20眼,所有患者均接受改良巩膜穿刺放液联合23G微创玻璃体切割术治疗。观察术中穿刺放液的成功率,手术前后视力、眼压变化情况,以及手术后视网膜复位率等情况。

结果：所有手术均一次顺利放出脉络膜上腔液体。患者术后视力较术前视力提高,差异有统计学意义(P<0.01)。术前眼压7.00±2.05mmHg,术后3mo时平均眼压为15.38±2.66mmHg,两者比较差异有统计学意义(P<0.01)。初次手术视网膜复位率为90%(18/20),最终视网膜复位率为95%(19/20)。

结论：改良巩膜穿刺放液在微创玻璃体切割术治疗脉络膜脱离型孔源性视网膜脱离中可简化手术操作,降低手术难度,减少术中并发症的发生。     

23-G微创玻璃体手术联合吊顶灯治疗上方球形孔源性视网膜脱离

目的 探讨应用23-G微创玻璃体手术联合吊顶灯治疗上方球形孔源性视网膜脱离(RRD)的临床疗效.方法 回顾性系列病例研究.50例50眼因上方球形RRD行23-G微创玻璃体手术.术中采用23-G两步法经结膜、巩膜穿刺置微套管,于下方6点位睫状体平坦部插入吊顶灯,在非接触式全视野镜下行23-G微创玻璃体手术联合眼内激光光凝封闭裂孔并注入全氟丙烷(C3Fs)填充.随访5～49个月,平均(23.9±1.3)个月.分析术中、术后并发症,术后结膜充血状态及眼部刺激征和炎症反应,分析视网膜解剖复位率、术后最佳矫正视力、眼压变化.数据采用配对t检验进行分析.结果 术中巩膜切口渗漏需缝合17眼(34％),无医源性裂孔、出血等术中并发症发生.术后结膜充血、眼部刺激征及炎症反应轻,1眼(2％)术后第1天出现一过性低眼压,翌日恢复,16眼(32％)一过性眼压升高,经降眼压治疗在平均4d内恢复正常.无出血、渗出、脉络膜脱离、眼内炎等术后并发症发生.一次手术视网膜复位49眼(98％),最终视网膜复位50眼(100％).42只黄斑脱离眼术前、术后最佳矫正视力分别为2.82±0.69、4.34±0.49,差异具有统计学意义(t=13.72,P＜0.01);8只黄斑未脱离眼术前、术后最佳矫正视力分别为4.61±0,19、4.70±0.19,差异无统计学意义(t=2.20,P＞0.05).结论 23-G微创玻璃体手术联合吊顶灯治疗上方球形RRD是一种安全有效的手术方法.     

黄斑孔伴视网膜周边裂孔的脉络膜脱离合并视网膜脱离的治疗

目的探讨黄斑孔伴视网膜周边裂孔的脉络膜脱离合并视网膜脱离的临床特点及治疗方法。方法回顾性分析黄斑孔伴视网膜周边裂孔的脉络膜脱离合并视网膜脱离86只眼,分析其共同的临床特点,并采用玻璃体切除联合硅油填充术进行治疗,观察其治疗效果。结果术后1个月最佳矫正视力眼前手动～数指31只眼,0．01—0．1者32只眼,0．1以上者23只眼。术后眼压9-23mmHg,平均眼压（13．2±0．5）mmHg（1mmHg=0．133kPa）,无严重并发症发生。结论采用玻璃体切除联合硅油填充治疗黄斑孔伴视网膜周边裂孔的脉络膜脱离合并视网膜脱离能取得较好效果。     

非接触广角观察系统辅助下内外路结合治疗孔源性视网膜脱离

目的 观察非接触广角观察系统及23G眼内照明辅助下的巩膜外垫压治疗孔源性视网膜脱离（RRD）的安全性及有效性。方法 6例RRD患者6只眼接受非接触广角观察系统及23G眼内照明辅助下的巩膜外垫压手术。其中,男性2例2只眼;女性4例4只眼。年龄23~66岁,平均年龄51岁。视网膜脱离发生距手术时间为2~13 d,平均时间为5.8 d。增生性玻璃体视网膜病变（PVR）分级均为B级。眼压9~15 mmHg（1 mmHg=0.133 kPa）,平均眼压12 mmHg。自睫状体平坦部插入23G导光纤维探头,在非接触广角观察系统辅助下检查全周视网膜并冷冻视网膜裂孔和变性区。在手术显微镜下完成巩膜切开引流视网膜下液及缝合硅胶带。手术结束时眼内注入无菌空气4只眼。手术后常规抗炎治疗,并随访观察不低于6个月。结果 6只患眼手术后视网膜均完全复位,视力均提高。结膜愈合良好,眼压12~19 mmHg,平均眼压15 mmHg。均无手术中及手术后并发症。结论 非接触广角观察系统及23G眼内照明辅助下的巩膜外垫压手术安全有效。与以往双目间接检眼镜辅助下的手术方式相比,手术成功率高,并发症少,手术时间短,患者手术中痛苦小。     

玻璃体切除术治疗牵拉性视网膜脱离34例

目的：探讨玻璃体切除术治疗牵拉性视网膜脱离的方法和疗效.方法：各种病因导致的牵拉性视网膜脱离34例36眼,行玻璃体切除术治疗,术后观察视力、视网膜复位情况及手术并发症等,随访3-6（平均3.8）mo.结果：术后视网膜复位,视力有不同程度的提高者32眼（89%）;术后3mo内视网膜再脱离4眼,其中2眼经再次手术后复位,2眼眼球萎缩未再手术.手术并发症主要有术中牵拉性裂孔、术中及术后玻璃体积血、术后高眼压、视网膜再脱离等.结论：玻璃体切除术是治疗牵拉性视网膜脱离的有效方法,尤其对于存在广泛固定牵拉、视网膜大范围脱离、玻璃体积血、合并严重的增殖性玻璃体视网膜病变的患者是唯一有效的手术方法.     

Primary 23-gauge vitreoretinal surgery for rhegmatogenous retinal detachment

AIM: To report the effectiveness and safety of primary 23-Gauge (G) vitreoretinal surgery for rhegmatogenous retinal detachment (RRD). METHODS: In this retrospective study, 49 eyes of 49 consecutive patients who underwent primary 23-G transconjunctival sutureless vitrectomy (TSV) for RRD between January 2007 and July 2009 at our institution were evaluated. RESULTS: Mean follow-up time was 8.9±7.7 months (1-28 months). Retinal reattachment was achieved with a single operation in 47(95.9%) of 49 eyes. In two eyes (4.1%), retinal redetachment due to new breaks was successfully treated with reoperation using the 23-G TSV system. Mean logMAR visual acuity was 2.01±0.47 preoperatively and 1.3±0.5 postoperatively (P<0.001, Paired t-test). Mean preoperative intraocular pressure (IOP) was 14.1±2.8mmHg. Mean postoperative IOP was 12.3±3.6mmHg at 1 day, 13.1±2.1mmHg at 1 week, 14.3±2.2mmHg at 1 month. Iatrogenic peripheral retinal break was observed in 1 eye (2.0%) intraoperatively. No sutures were required to close the scleral or conjunctival openings, and no eyes required convertion of surgery to 20-G vitrectomy. CONCLUSION: Primary 23-G TSV system was observed to be effective and safe in the treatment of RRD.     

25-Gauge transconjunctival sutureless pars plana vitrectomy

PURPOSE: To evaluate the effectiveness, feasibility, and safety of the transconjunctival sutureless vitrectomy (TSV) system for a vriety of vitreoretinal diseases. METHODS: In this retrospective study, the authors evaluated 71 eyes of 63 patients who underwent pars plana vitrectomy (PPV) with the 25-gauge TSV system. The indications for surgical intervention were diabetic vitreous hemorrhage (29 eyes), diabetic macular edema (14 eyes), macular epiretinal membrane (13 eyes), endophthalmitis (5 eyes), vitreous opacities secondary to Behcet's disease (4 eyes), vitreous hemorrhage secondary to branch retinal vein occlusion (4 eyes), and vitreous hemorrhage secondary to age-related macular degeneration (2 eyes). Epiretinal membrane and internal limiting membrane removal, endolaser photocoagulation, and air-fluid exchange were performed when required. RESULTS: Mean follow-up was 3.6 months (range 1-8 months). Mean overall visual acuity (VA) was counting fingers (range light perception to 0.4) preoperatively and 0.2 (range 0.1 to 0.8) postoperatively (p=0.000). Statistically significant VA improvement was observed in eyes with vitreous hemorrhage, diabetic macular edema, and macular epiretinal membrane. VA improved postoperatively in all eyes with endophthalmitis and vitreous opacities secondary to Behcet's disease. The surgery was completed without conjunctival and scleral suturing in all eyes. Mean intraocular pressure (IOP) was 17.2 mmHg (range 10-26 mmHg) preoperatively, 12.4 mmHg (range 6-24 mmHg) on the first postoperative day, 16.6 mmHg (range 10-33 mmHg) at 1 week, and 15.4 mmHg (range 10-20 mmHg) at 1 month postoperatively. On the first postoperative day, IOP was below 10 mmHg (between 6 and 9 mmHg) in 12 eyes (16.9%). In these eyes, IOP was normalized within 1 week without affecting the visual outcome. Five eyes (7%) had transient increase of IOP controlled by topical antiglaucomatous medications. Vitreous washout using 25-gauge TSV system was performed in two eyes, in which vitreous hemorrhage recurred. CONCLUSIONS: The TSV system was observed to be feasible, effective, and safe for a variety of vitre o retinal diseases. This minimally invasive and completely sutureless (transconjunctival) technique appears to decrease the convalescence period, operating time, and postoperative inflammatory response, and improve patient comfort.     

Vitrectomy, lensectomy and silicone oil tamponade in the management of retinal detachment associated with choroidal detachment

AIM:To report the results of combined vitrectomy, lensectomy and silicone oil (SO) tamponade in treating primary rhegmatogenous retinal detachment (RRD) associated with choroidal detachment (CD).METHODS:A retrospective, consecutive and case series study of 21 subjects with concurrent RRD associated with CD was conducted. All subjects underwent a standard three-port 20G pars plana vitrectomy (PPV) with lensectomy and silicone oil tamponade. Mean follow-up time was 8 months (rang from 4 to 19 months). The primary and final anatomic success rate, visual acuity and final intraocular pressure(IOP) were recorded and analyzed.RESULTS:Of 21 subjects, 8 were women and 13 were men. Age at presentation ranged from 22 to 75 years (mean 57.4 years). The presenting vision ranged from light perception to 0.15. The initial IOP ranged from 3mmHg to 12mmHg (mean 6.2mmHg). All eyes were phakic except one pseudophakic. No intraocular lens was implanted during the primary surgical intervention. Fifteen of 21 (71.4%) eyes had retina reattached after one operation. Six eyes had recurrent inferior retinal detachment due to proliferation. Five of them were successfully reattached after one or more additional operations. Mean IOP at final follow-up was 15.2mmHg (range from 8mmHg to 20mmHg). One case declined for further operation. The final reattachment rate was 95.2%. Visual acuity improved in 19 (90.5%) eyes, was unchanged in 1 (4.8%) eye and decreased in 1 (4.8%) eye.CONCLUSION:Combination of vitrectomy, lensectomy and silicone tamponade is an effective method in treating RRD associated with CD, reducing the incidence of postoperative hypotony.     

Retinal detachment in eyes treated with Aurolab aqueous drainage implant for refractory glaucoma - Incidence and outcomes

Purpose:To analyze the incidence of rhegmatogenous retinal detachment (RRD) in patients who have undergone prior Aurolab aqueous drainage implant (AADI) surgery and report outcomes in terms of anatomic, visual acuity, and intraocular pressure (IOP) findings.Methods:Case records of all patients who underwent RRD repair after AADI surgery from 2013 to 2019 were retrospectively analyzed. Data collected included patient demographics, ocular examination findings at all visits including IOP and best-corrected visual acuity (BCVA) and clinical findings related to RRD both at baseline and postoperatively.Results:Ten eyes of nine patients were included in study. The mean age of patients was 28.2 years (median: 15 years, range: 6–83 years). Mean duration between AADI and RRD was 14 months (median 2.5 months; range 2 days-72 months). All eyes underwent pars plana vitrectomy with silicon oil injection. The preoperative LogMAR BCVA (logarithm of the minimum angle of resolution) was 2.52 ± 0.15 which improved to 2.29 ± 0.58 at final follow-up; however, only one eye had vision ≥ 20/400 largely due to recurrent RRD and advanced glaucomatous disc damage. Postoperatively retina was attached in 6 eyes (60%) and IOP was ≤ 21 mmHg in 5 out of 6 eyes with anatomic successConclusion:The incidence of RRD following AADI was found to be 0.86% in our study. Pars plana vitrectomy (PPV) with silicon oil tamponade was the preferred approach in the management of these eyes with IOP being well controlled post PPV. However, visual acuity outcomes were largely unsatisfactory due to recurrent RRD and preexisting advanced glaucoma.     

新生血管性青光眼不同治疗方法疗效对比分析

目的:对比三种不同方法治疗新生血管性青光眼(neovasular glaucoma,NVG)的疗效。方法:对51例54眼NVG患者进行回顾性观察和分析,根据患者的不同手术方式及治疗方法分为3组。A组27例28眼,行单纯睫状体光凝术;B组14例14眼,avastin玻璃体腔内注射1wk后行小梁切除术联合丝裂霉素C(MMC)术中敷贴;C组10例12眼,avastin玻璃体腔内注射1wk后行玻璃体切割术+引流阀植入术。B,C两组均在治疗过程中尽早完成全视网膜光凝术(panretinal photocoagulation,PRP)。结果:患者出院时平均眼压:A组为25.75±1.44mmHg,手术成功率为21%;B组为12.86±1.37mmHg,手术成功率为86%;C组为16.58±1.85mmHg,手术成功率为83%。结论:三种方法均不同程度降低眼压。但睫状体光凝术在术后1wk内多数患者眼压控制不在正常范围,故有视力眼不宜选择单纯睫状体光凝术。抗血管内皮生长因子(VEGF)类药物联合抗青光眼手术可在1wk内有效控制眼压,对于保存患者视功能明显优于单纯睫状体光凝术。     

玻璃体切割治疗弥漫性糖尿病黄斑水肿疗效观察

目的:研究玻璃体切割治疗弥漫性糖尿病黄斑水肿的临床效果。方法:收集2004-03/2006-07在我院因弥漫性糖尿病黄斑水肿性行玻璃体切割方法治疗的患者23例(23眼),所有患者均严格控制血糖、血压,术前均详细检查视力、眼压、裂隙灯、检眼镜眼底、荧光血管造影(fluorescein fundus angiography,FFA)、光学相干断层扫描(optical coherence tomography,OCT),分别记录术前术后1,3,6,12mo视力及黄斑厚度,进行对比,并观察手术后并发症,平均随访14.5±1.2mo。结果:所有患者均顺利进行玻璃体手术治疗,其中有8例患者在曲安奈德(triamcinolone acetonide,TA)辅助下完成玻璃体手术,术前患者平均视力0.24±0.15,术后1,3,6,12mo平均视力0.19±0.14,0.25±0.16,0.28±0.15,0.32±0.19,术后12mo与术前矫正视力对比有显著性差异,术前黄斑厚度平均OCT值438±169μm,术后1,3,6,12mo平均OCT值为317±123,263±87μm,237±6,228±41μm,与术前分别对比均有显著性差异。术中2例出现医源性网膜裂孔,激光封口,无患者术后出现玻璃体出血,虹膜新生血管,视网膜前膜,无患者行白内障手术。结论:玻璃体切割手术治疗弥漫性黄斑水肿可在短期内明显减轻黄斑水肿,并逐步改善患者视功能,其远期效果需进一步观察。     

The safety and efficacy of transconjunctival sutureless 23-gauge vitrectomy

PURPOSE: To evaluate the efficacy and safety of vitreoretinal surgery using a 23-gauge transconjunctival sutureless vitrectomy (TSV) system for various vitreoretinal diseases. METHODS: A retrospective, consecutive, interventional case series was performed for 40 eyes of 40 patients. The patients underwent vitreoretinal procedures using the 23-gauge TSV system, including idiopathic epiretinal membrane (n=7), vitreous hemorrhage (n=11), diabetic macular edema (n=10), macular hole (n=5), vitreomacular traction syndrome (n=5), diabetic tractional retinal detachment (n=1), and rhegmatogenous retinal detachment (n=1). Best corrected visual acuity (BCVA), intraocular pressure (IOP), and intra- and post-operative complications were evaluated. RESULTS: Intraoperative suture placement was necessary in 3 eyes (7.5%). The median BCVA improved from 20/400 (LogMAR, 1.21+/-0.63) to 20/140 (LogMAR, 0.83+/-0.48) at 1 week (p=0.003), 20/100 (LogMAR, 0.85+/-0.65) at 1 month (p=0.002), 20/100 (LogMAR, 0.73+/-0.6) at 3 months (p=0.001). In 1 eye, IOP was 5 mmHg at 2 hours and 4 mmHg at 5 hours, but none of the eyes showed hypotony after 1 postoperative day. No serous postoperative complications were observed during a mean follow-up of 8.4+/-3.4 months (range 3-13 months) CONCLUSIONS: The 23-gauge TSV system shows promise as an effective and safe technique for a variety of vitreoretinal procedures. It appears to be a less traumatic, more convenient alternative to 20-gauge vitrectomy in some indications.     

巩膜外手术治疗孔源性视网膜脱离的临床分析

探讨两种巩膜外手术方式治疗孔源性视网膜脱离的效果。 方法：选取我院孔源性视网膜脱离（RRD）患者220例220眼,其中复杂性视网膜脱离70例70眼,非复杂性视网膜脱离150例150眼。分别实施巩膜环扎+外加压+冷凝+放液（或不放液）术及巩膜外加压+冷凝+放液（或不放液）术。 结果：两种手术方式对复杂性RRD和非复杂性RRD的效果均无统计学意义（P>0.05）,但非复杂性视网膜脱离患者一次性成功率为89.3％,而复杂性视网膜脱离患者一次性成功率仅为72.9％。 结论：巩膜外手术对非复杂性视网膜脱离是一种行之有效的手术。而巩膜环扎在视网膜脱离手术中并非完全必要     

角膜入路23-G玻璃体切除在眼外伤的应用

目的观察透明角膜入路的23-G微创玻璃体手术在一期眼外伤处理中的效果。方法回顾性系列病例研究。对26例（26只眼）复杂眼外伤采用角膜入路的晶状体切除及前部玻璃体切除术：在近角膜缘的透明角膜上用23-G穿刺刀做两个切口,分别置微套管,一侧与灌注管相连,另一侧伸入玻切头。通过两个微套管进行角膜入路的晶状体切除及前段玻璃体切除。结果术中无并发症发生,术后随访结束时最佳矫正视力0．5及以上者3只眼（11．54％）,0．1～0．4者8只眼（30．77％）,0．02—0．08者12只眼（46．15％）,数指及以下者3只眼（11．54％）。术后第3天平均眼压为（13．26±4．83）mmHg,术后第7天平均眼压为（14．65±3．91）mmHg（1mmHg=0．133kPa）。18只眼二期植入人工晶状体,9眼经玻璃体视网膜手术处理后,视网膜复位,保留了眼球。结论透明角膜入路的23．G微创玻璃体手术是一期处理眼外伤的有效方法。     

23G微创玻璃体切割术在孔源性视网膜脱离中的应用

目的：评估23G经结膜无缝线玻璃体切割手术治疗孔源性视网膜脱离的安全性及有效性。 方法：前瞻性选择2010-03/2011-06共26例26眼不伴有严重增生性病变的孔源性视网膜脱离病历,均行23G切割手术。记录术前、术后的最佳矫正视力（BCVA）、眼压,术中及术后并发症。 结果：一次性复位视网膜21例（81%）,最终复位视网膜25例（96%）。术后3mo最佳矫正视力较术前提高21例（80%）,不变3例（12%）,下降2例（8%）。术后1d眼压较术前下降,此差异有统计学意义（P<0.01）。低眼压（≤6mmHg）2例,持续2wk,但未发生脉络膜脱离。 结论：23G手术治疗孔源性视网膜脱离解剖复位率满意,术后视力改善明显。但23G微创手术的优势并没有在孔源性视网膜脱离的手术中得到充分体现,反而要面临更高的手术失败的风险。